Multi-Omics Analysis of the Anti-tumor Synergistic Mechanism and Potential Application of Immune Checkpoint Blockade Combined With Lenvatinib

Multi-Omics Analysis of the Anti-tumor Synergistic Mechanism and Potential Application of Immune Checkpoint Blockade Combined With Lenvatinib

The combination of immune-checkpoint blockade (ICB) and lenvatinib has demonstrated robust clinical effects that are superior to those of monotherapies, but the synergistic anti-tumor mechanisms remain unclear. Exploring the synergistic molecular mechanisms and early identifying potential applicatio...

Full description

Bibliographic Details
Main Authors:	Yuting Lu, Jiangtao Jin, Qi Du, Min Hu, Yuhan Wei, Miao Wang, Hongzhong Li, Qin Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-09-01
Series:	Frontiers in Cell and Developmental Biology
Subjects:	immune-checkpoint blockade lenvatinib synergistic mechanism multi-omics analysis malignancy
Online Access:	https://www.frontiersin.org/articles/10.3389/fcell.2021.730240/full

Similar Items

The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma
by: Yun Wang, et al.
Published: (2020-12-01)

Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD−1/PD-L1 Checkpoint Blockade
by: Tomoko Aoki, et al.
Published: (2020-10-01)

Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma)
by: Walid Shalata, et al.
Published: (2021-07-01)

Combining photothermal ablation-based vaccine with immune checkpoint blockade for synergistic osteosarcoma immunotherapy
by: Xingyu Zhao, et al.
Published: (2021-01-01)

Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma
by: Na Zhang, et al.
Published: (2020-11-01)

In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade
by: Eric Bartee, et al.
Published: (2017-05-01)

Case Report: Significant Response to the Combination of Lenvatinib and Immune Checkpoint Inhibitor in a Patient With Heavily Pretreated Metastatic Triple Negative Breast Cancer
by: Jin Sun Lee, et al.
Published: (2021-01-01)

Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
by: Yanna Lei, et al.
Published: (2021-03-01)

Smoldering myocarditis following immune checkpoint blockade
by: Timothy G. Norwood, et al.
Published: (2017-11-01)

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
by: Florent Petitprez, et al.
Published: (2020-05-01)

Mining Synergistic Microbial Interactions: A Roadmap on How to Integrate Multi-Omics Data
by: Joao Pedro Saraiva, et al.
Published: (2021-04-01)

Prospects of immune checkpoint blockade and vaccine-based immunotherapy for glioblastoma
by: Tietze Stefanie, et al.
Published: (2021-04-01)

Recent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade
by: Rachel L. Y. Ho, et al.
Published: (2021-07-01)

Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma
by: Yusuke Kawamura, et al.
Published: (2020-10-01)

Molecular T-Cell Repertoire Analysis as Source of Prognostic and Predictive Biomarkers for Checkpoint Blockade Immunotherapy
by: Ilenia Aversa, et al.
Published: (2020-03-01)

Clonal tracing reveals diverse patterns of response to immune checkpoint blockade
by: Shengqing Stan Gu, et al.
Published: (2020-10-01)

Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity
by: Wei Xie, et al.
Published: (2019-11-01)

Obatoclax, the pan-Bcl-2 inhibitor sensitizes hepatocellular carcinoma cells to promote the anti-tumor efficacy in combination with immune checkpoint blockade
by: Jingye Li, et al.
Published: (2021-08-01)

Photothermal therapies to improve immune checkpoint blockade for cancer
by: Preethi B. Balakrishnan, et al.
Published: (2020-12-01)

Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
by: Keisuke Koroki, et al.
Published: (2021-04-01)

Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade Therapy
by: Qi-jie Zhang, et al.
Published: (2021-04-01)

Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade
by: Elizabeth I. Buchbinder, et al.
Published: (2021-04-01)

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
by: Xiaolei Li, et al.
Published: (2018-02-01)

Nanosonosensitizer-Augmented Sonodynamic Therapy Combined with Checkpoint Blockade for Cancer Immunotherapy
by: Lin X, et al.
Published: (2021-03-01)

Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma
by: Jonathan T. Hunt, et al.
Published: (2021-08-01)

Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction
by: Hong Wei, et al.
Published: (2019-09-01)

Integrative clinical and molecular analysis of advanced biliary tract cancers on immune checkpoint blockade reveals potential markers of response
by: Jingjing Li, et al.
Published: (2020-08-01)

Combination immune checkpoint blockade as an effective therapy for mesothelioma
by: Vanessa S. Fear, et al.
Published: (2018-10-01)

Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract
by: Michael Dougan
Published: (2017-11-01)

Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer
by: Yaru Tian, et al.
Published: (2019-06-01)

Pre-treatment tumor neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcome
by: Shaokang Ma, et al.
Published: (2020-01-01)

Impact of Local Liver Irradiation Concurrent Versus Sequential with Lenvatinib on Pharmacokinetics and Biodistribution
by: Tung-Hu Tsai, et al.
Published: (2021-03-01)

Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer
by: Isobel S. Okoye, et al.
Published: (2017-09-01)

Shunt occlusion prior to lenvatinib administration prevents hepatic encephalopathy and hyperammonemia
by: Ai Kuwahara, et al.
Published: (2020-08-01)

Prediction of Immune-Checkpoint Blockade Monotherapy Response in Patients With Melanoma Based on Easily Accessible Clinical Indicators
by: Hwa Kyung Byun, et al.
Published: (2021-05-01)

Unexpected Favorable Outcome to PD-1 Antibody Plus Lenvatinib in a Patient With Recurrent Intestinal Follicular Dendritic Cell Sarcoma: A Case Report and Literature Review
by: Yanna Lei, et al.
Published: (2021-09-01)

Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade
by: Alice Mougel, et al.
Published: (2019-03-01)

Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China
by: Yun Zhu, et al.
Published: (2021-09-01)

Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
by: Maria Georganaki, et al.
Published: (2018-12-01)

Mechanisms of immunogenic cell death and immune checkpoint blockade therapy
by: Richard A. Lin, et al.
Published: (2021-06-01)

Cannot write session to /tmp/vufind_sessions/sess_1133nb5cd3jpgu932i81thhnrp